Syndax Pharmaceuticals Price to Free Cash Flow Ratio 2015-2024 | SNDX

Syndax Pharmaceuticals price to free cash flow ratio from 2015 to 2024. Price to free cash flow ratio can be defined as

Syndax Pharmaceuticals Price to Free Cash Flow Ratio 2015-2024 | SNDX

Syndax Pharmaceuticals price to free cash flow ratio from 2015 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$152.1B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$120.1B
Gilead Sciences (GILD)$115.4B
CSL (CSLLY)$89B
Regeneron Pharmaceuticals (REGN)$82.4B
GSK (GSK)$70.7B
Argenex SE (ARGX)$37.2B
Alnylam Pharmaceuticals (ALNY)$32.6B
BioNTech SE (BNTX)$28.4B
Biogen (BIIB)$23.4B
Illumina (ILMN)$22.9B
BeiGene (BGNE)$20.9B
Moderna (MRNA)$16.6B
Incyte (INCY)$14.4B
Genmab (GMAB)$14.2B
Insmed (INSM)$13.4B
Sarepta Therapeutics (SRPT)$12.7B
BioMarin Pharmaceutical (BMRN)$12.6B
Bio-Techne Corp (TECH)$12B
Vaxcyte (PCVX)$11.8B
Exact Sciences (EXAS)$11.5B
Exelixis (EXEL)$10.4B
QIAGEN (QGEN)$9.9B
Revolution Medicines (RVMD)$9.7B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8.4B
Ascendis Pharma (ASND)$8.3B